Introduction
Pilocarpine-induced epilepsy rodent models have been frequently used to investigate underlying mechanisms of human temporal lobe epilepsy (TLE). 3, 10, 11, 14, 16 Pilocarpine treatment provokes long-lasting status epilepticus (SE) in the animals. The animals have spontaneous recurrent seizures after a latent seizurefree phase characterized by development of hippocampal damage. Some studies have suggested that free radicals such as nitric oxide (NO) which is synthesized from arginine by NO synthase (NOS) plays a crucial role in the above pathogenesis. 3, 10, 11, 14, 16 Edaravone (MCI-186) is a novel radical scavenger that protects neurons by inhibiting vascular endothelial cell injury and by ameliorating neuronal damage caused by acute brain ischemia. [18] [19] [20] Edaravone was found to have antioxidant effects, quenching OH and inhibiting both OH-dependent and OH-independent lipid peroxidation, and to exert inhibitory effects on both water-soluble and lipid-soluble peroxyl radical-induced peroxidation systems. [18] [19] [20] Furthermore, edaravone had antioxidant activities, quenching not only OH but also other free radical species such as superoxide and NO radicals. [18] [19] [20] Recent results indicate that edaravone exerted neuroprotective effects by reducing both neuronal NOS (nNOS) and inducible NOS (iNOS) and increasing endothelial NOS (eNOS) in acute ischemia rodent models. 13, 20, 22 However, the possibility that edaravone might have neuroprotective effects on hippocampal damage in pilocarpine-induced seizures has not yet been studied. In the present study, we investigated the neuroprotective effects of edaravone on pilocarpine-induced seizures in rats and NOS expression alterations in the hippocampus of the animals.
Methods
Adult male Wistar rats (200-250 g) were housed individually and kept on a 12-h light/dark cycle. All experimental manipulations were conducted in accordance with the guidelines of Oita University Animal Care Committee. Free radical scavenger Edaravone Nitric oxide synthase Pilocarpine Rat
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Purpose: Edaravone (MCI-186) is a newly developed antioxidative radical scavenger for the treatment of acute cerebral infarction, exerting neuroprotective effects against ischemic insult. The neuroprotective effects of edaravone on pilocarpine-induced seizures in rats were investigated. Methods: Rats were treated intraperitoneally with saline or edaravone (1-30 mg/kg), applied 30 min before pilocarpine hydrochloride (330 mg/kg). The onset of status epilepticus (SE) and mortality were recorded for a period of at least 3 days. The cell loss and immunoreactivities of nitric oxide synthase (NOS) in the hippocampus from control and the day 3 rats after SE, treated with saline or edaravone, were evaluated. Results: Edaravone (1 mg/kg) significantly prevented cell loss in the hippocampus after SE while easier inducing SE. The higher dose of drug could not induce SE significantly but tended to increase the rate of mortality. Inducible NOS (iNOS) expression was significantly decreased in the hippocampus from day 3 rats treated with 1 mg/kg edaravone, compared with saline group, while neuronal NOS (nNOS) and iNOS significantly increased in the hippocampus treated with saline, compared with control group. Significant alteration of endothelial NOS (eNOS) expression in the hippocampus among control group, saline group, and edaravone group was not shown. Conclusions: Edaravone may act as a neuroprotector for the hippocampus after SE by reducing at least iNOS although the low dose of drug easier induces SE because of preventing an endogenous antiepileptic effect of NO.
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The animals (n = 155) were pretreated with atropine methylbromide (1 mg/kg s.c.). Five rats received saline i.p. and no pilocarpine hydrochloride (PIL) (control group). One hundred and fifty rats received PIL (330 mg/kg i.p.), of which 41 were treated with saline (PIL/saline group) and 109 with different doses of edaravone (1, 3, 10, and 30 mg/kg i.p.) (n = 25, 28, 28, and 28). After 40 min, SE was terminated by the injection of diazepam (4 mg/kg i.p.). All animals including the control were observed for a period of at least 3 days after the injection of PIL.
Five rats in PIL/saline group, 5 in PIL/edaravone 1 mg/kg group, 1 in PIL/edaravone 10 mg/kg group and 1 in PIL/edaravone 30 mg/ kg group were alive 3 days after SE. The rats which survived were deeply anesthetized with an overdose of sodium pentobarbital i.p. and sequentially perfused transcardially with 4% paraformaldehyde. Brains were removed and cut en bloc in the coronal plane, and embedded in paraffin.
The 3-mm thick coronal sections through the hippocampus were stained with hematoxylin and eosin as a counterstain and then stained immunohistochemically using the labeled streptoavidin-biotin method (Dako Lab Kit, Dako, Kyoto, Japan) at Fig. 1 . Bar graphs show the averaged hippocampal neuron densities from the control and day 3 rats after SE, treated with PIL/saline or PIL/edaravone 1 mg/kg. The neurons in all hippocampal subfields from the rats treated with PIL/saline were significantly decreased compared with those of the control while CA1 neurons from the rats treated with PIL/edaravone 1 mg/kg were significantly decreased compared with those of the control; *P < 0.05 and **P < 0.01 (Student's t-test). Error bars indicate the mean AE S.E.M. Fig. 2 . Immunohistochemical staining for nNOS in the hippocampus from day 3 rats after SE, treated with PIL/saline or PIL/edaravone 1 mg/kg. nNOS expression was not increased in the hippocampus from a rat treated with PIL/edaravone 1 mg/kg while it was slightly increased in the hippocampus from a rat treated with PIL/saline, compared with a control. Immunohistochemical staining for iNOS in the hippocampus from day 3 rats after SE, treated with PIL/saline or PIL/edaravone 1 mg/kg. iNOS expression was not increased in the hippocampus from a rat treated with PIL/edaravone 1 mg/kg while it was markedly increased in the hippocampus from a rat treated with PIL/saline, compared with a control. Fig. 4 . Immunohistochemical staining for eNOS in the hippocampus from day 3 rats after SE, treated with PIL/saline or PIL/edaravone 1 mg/kg. eNOS expression was not increased in the hippocampus from a rat treated with PIL/edaravone 1 mg/kg while it was little increased in the hippocampus from a rat treated with PIL/saline, compared with a control.
designated times (control, 1 and 3 days from SE). The following primary antibodies were used: rabbit polyclonal antibodies against human brain neuronal NOS (nNOS:CHM, CA, USA; dilution 1:2500-5000), inducible NOS (iNOS:BOX, CA, USA; dilution 1:1000), and endothelial NOS (eNOS:ABR, CO, USA; dilution 1:100). Cells numbers were counted in different hippocampal subfields (dentate gyrus, Hilus, CA1, and CA3) of the dorsal hippocampus in control, rats treated with PIL/saline, and rats with PIL/edaravone. Quantification was performed at 400Â magnification with an ocular grid (100 boxes of 2.5 mm Â 2.5 mm) after two fields were randomly selected in the same section. Statistical significance of differences from control was determined by analysis of Fisher's exact tests in SE induction and mortality, one-way ANOVA on ranks in latency to SE and Student's t-test in cell loss in the hippocampus.
From control, rats treated with PIL/saline, and rats with PIL/ edaravone we evaluated immunoreactivities of nNOS, iNOS, and eNOS in the different subfields (dentate gyrus, Hilus, CA1, and CA3) of dorsal hippocampus according to four grades staining score: no staining 0, slight staining 1, moderate staining 2, or dense staining 3. Statistical significance of difference between control group and PIL/saline group, or between PIL/saline group and PIL/edaravone group were determined by analysis of Wilcoxon signed rank test. A value of p < 0.05 was considered as significant, and p < 0.01 as highly significant.
Results
Animals treated with PIL/edaravone 1 mg/kg showed a significantly higher incidence of SE than those treated with PIL/ saline. The rats treated with PIL/higher-dose edaravone revealed no significant difference in incidence of SE compared with those treated with PIL/saline ( Table 1) . Edaravone exerts an dosedependant increase in the rate of mortality, while showing no significant proconvulsant effect in doses higher than 1 mg/kg ( Table 1) . The latency to SE induced by PIL is increased in edaravone treated rats. There was no significant difference in latency between PIL/edaravone group and PIL/saline group ( Table 1) . As well as control (n = 5), rats that were alive 3 days after SE, treated with PIL/saline (n = 5) or PIL/edaravone 1 mg/kg (n = 5), were selected for data analysis of cell loss and NOS expression in the hippocampus.
It was only CA1 neurons from the day 3 rats after SE, treated with PIL/edaravone 1 mg/kg, that were significantly decreased, compared with those of the control while neurons in all hippocampal subfields from the day 3 rats after SE, treated with PIL/saline, were significantly decreased, compared with the control (Fig. 1) .
nNOS expression was significantly increased in the CA3 neurons from day 3 rats after SE, treated with PIL/saline, compared with the control (p < 0.01) (Figs. 2 and 5 ). iNOS expression was significantly increased in the Hilus, CA3, and CA1 neurons from day 3 rats after SE, treated with PIL/saline, compared with the control (p < 0.01) (Figs. 3 and 5 ). The day 3 rats treated with PIL/edaravone 1 mg/kg showed significant decreased expression of iNOS in the Hilus and CA3 than those treated with PIL/saline (p < 0.05) (Figs. 3 and 5 ). Significant alteration of eNOS expression in the hippocampus among control group, PIL/saline group, and PIL/edaravone group was not shown (Figs. 4 and 5 ).
Discussion
NO is generated from L-arginine and molecular oxygen by three NOS isoforms. 1, 9 Some reports have showed differential roles of NOS isoforms in the pathogenesis for brain ischemia. 6, 7, 15, 21 nNOSand iNOS-derived NO is harmful during acute brain ischemia 2,5,9,13 while eNOS-derived NO plays a protective role, helping to preserve blood flow. 9, 13 Recent studies indicated that edaravone exerts neuroprotective effects by reducing both nNOS and iNOS and by increasing eNOS in acute ischemia rodent models. 13, 20, 22 In the similar mechanism, the efficacy of edaravone for brain and spinal cord injury has also been reported. 4, 12, 17 The present study is a first report showing that edaravone has neuroprotective effects on hippocampal damage after SE. Our results showed that edaravone had neuroprotective effects on the rat hippocampus after pilocarpine-induced SE by reducing at least iNOS though the low dose of drug easier induced SE. The neuroprotective effects of edaravone which were indicated in this study may result especially from iNOS reduction but probably has no relation with eNOS alteration directly. The low dose of edaravone may be unable to increase eNOS expression in the hippocampus after SE. . NOS intensity score in the hippocampus from the control and day 3 rats after SE, treated with PIL/saline or PIL/edaravone 1 mg/kg. iNOS expression was significantly decreased in the hippocampus from day 3 rats treated with PIL/ edaravone 1 mg/kg, compared with saline group, while nNOS and iNOS significantly increased in the hippocampus treated with PIL/saline, compared with control group. Significant alteration of endothelial NOS (eNOS) expression in the hippocampus among control group, PIL/saline group, and PIL/edaravone group was not shown; **P < 0.01 and The previous studies have demonstrated that NOS inhibitors acting on both nNOS and eNOS have proconvulsant. 3, 10, 16 It was speculated that proconvulsant effects of NOS inhibition are associated with the failure of a retrograde inhibition exerted by NO on NMDA receptors. The low dose of edaravone may easier induce SE because it makes the retrograde inhibition by NO cease to exert. On the other hand, eNOS induced by higher dose of edaravone, which is reported to have anticonvulsant effects, 8 may make it hard to induce SE. However, if SE begins once, it may be repeated many times because the retrograde inhibition by NO cannot exert entirely.
Our new data suggests that edaravone probably has neuroprotective effects on human brain after SE, but for the purpose of clinical use, it should be studied whether the drug has neuroprotective effects without induction of SE in doses less than 1 mg/kg.
